CVS Has 'Real Value,' Jim Cramer Says: Micron Had An 'Amazing' Quarter

When asked about CVS Health Corporation CVS on CNBC's “Mad Money Lightning Round,” Jim Cramer said, “I think there's real value here.”

On Oct. 10, Barclays analyst Andrew Mok upgraded CVS Health from Equal-Weight to Overweight and raised the price target from $63 to $82.

Don’t Miss Out:

  • This billion-dollar fund has invested in the next big real estate boom, here's how you can join for $10.
    This is a paid advertisement. Carefully consider the investment objectives, risks, charges and expenses of the Fundrise Flagship Fund before investing. This and other information can be found in the Fund's prospectus. Read them carefully before investing.
  • Your biggest returns may not come from the stock market. Invest the way colleges, pension funds, and the 1% do. Get started investing in commercial real estate today.

Cramer also recommends buying Micron Technology, Inc. MU, saying it had an “amazing” quarter.

On Oct. 8, Keybanc analyst John Vinh maintained Micron Technology with an Overweight and lowered the price target from $145 to $135.

Although Cramer believes Old Dominion Freight Line ODFL will have a good year, but he prefers the stock of Union Pacific UNP.

On Oct. 9, Citigroup analyst Ariel Rosa initiated coverage on Old Dominion Freight Line with a Neutral rating and announced a price target of $206.

The “Mad Money” host recommended not touching American Tower AMT.

On Oct. 10, Barclays analyst Tim Long maintained American Tower with an Overweight and raised the price target from $223 to $255.

Cramer said Howmet Aerospace Inc. HWM is going higher, adding that it is one of the greatest stocks of his time.

Howmet Aerospace will announce its third quarter 2024 financial results on Wednesday, Nov. 6.

Trending: A billion-dollar investment strategy with minimums as low as $10 — you can become part of the next big real estate boom today.
This is a paid advertisement. Carefully consider the investment objectives, risks, charges and expenses of the Fundrise Flagship Fund before investing. This and other information can be found in the Fund's prospectus. Read them carefully before investing.

ADMA Biologics ADMA is a “very speculative” stock, Cramer said.

On Sept. 20, Cantor Fitzgerald analyst Kristen Kluska reiterated ADMA Biologics with an Overweight and maintained a $20 price target.

Cramer recommended buying Modine Manufacturing MOD. “It's just one of these great metal-bending companies,” he added.

On Sept. 24, DA Davidson analyst Matt Summerville maintained Modine Manufacturing with a Buy and raised the price target from $140 to $155.

Robinhood HOOD is a buy, Cramer said.

On Oct. 8, Piper Sandler analyst Patrick Moley maintained Robinhood with an Overweight and maintained a $27 price target.

Wondering if your investments can get you to a $5,000,000 nest egg? Speak to a financial advisor today. SmartAsset’s free tool matches you up with up to three vetted financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.

Keep Reading:

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: MarketsBZ-REALESTATE
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!